Drug discovery: From target to translation
Research models and tools to help advance oncology drug discovery and development
Drug discovery is a complex, rarely linear journey – from identifying and validating promising targets to understanding drug response, evaluating therapeutic potential and generating evidence that can support translation.
With many major challenges throughout the process – for example the high drug failure rate due to poorly predictive preclinical models – whatever stage you are at, having the right research models can help you ask better questions, explore new possibilities, avoid roadblocks and reduce attrition.
CancerTools provides access to a growing portfolio of researcher-developed cancer research tools and advanced cancer models such as cancer cell lines, more predictive patient-derived cell lines (PDC) and xenograft (PDX) models, mouse models, exclusive antibodies and more to support your research across the drug discovery journey. By sharing knowledge and working collaboratively, we can help advance cancer research together.
Supporting pharma, biotech, CRO and CDMO organisations
Whether you’re advancing a lead asset, validating a novel target, supporting client studies or generating translational evidence, access to the right preclinical models can help reduce uncertainty and improve development decisions.
Why CancerTools?
Access innovative tools developed by leading cancer researchers and institutes worldwide
Patient-derived models designed to reflect clinically relevant disease biology
Simple licensing with multiple tools available through a single agreement
Expert support from IP and tech-transfer specialists
| For pharmaceutical companies | For biotech companies | For CROs and CDMOs |
|---|---|---|
| Accelerate target validation, biomarker discovery and translational research using clinically relevant cancer models. | Advance programmes with access to specialist cancer models without the time and cost of developing them internally. | Expand your service offering with access to specialist cancer research models and reagents that support client projects across discovery and translational research. |
| Use CancerTools to: – Validate therapeutic targets – Investigate mechanisms of action – Evaluate efficacy and resistance – Support biomarker development – Generate evidence to inform clinical strategy | CancerTools can help you: – Build proof-of-concept data – Strengthen investor and partner discussions – Demonstrate therapeutic relevance – Generate evidence for programme progression | Areas of application include: – Candidate evaluation – Target validation – Drug screening – Resistance studies – Translational research services |
Research tools for every stage of drug discovery:
1. Target identification and validation
Understanding the molecular mechanisms driving cancer can reveal potential vulnerabilities and therapeutic targets.
CancerTools provides access to cancer models and reagents that can help you investigate disease biology, molecular pathways, target expression, function, and therapeutic response across different genetic backgrounds.
Explore key models below for target identification and validation studies
2. High throughput screening, hit discovery and lead optimisation
As potential therapeutic compounds emerge, characterising how they affect cancer cells is an important part of drug development.
Our cell lines, antibodies and genetically defined models can support your studies in:
- Candidate drug activity
- Cellular response and therapeutic vulnerabilities
- Mechanism of action
- Pathway activity
- Drug sensitivity and resistance
- Identifying therapeutic candidates
Explore key models below to build a deeper understanding of therapeutic response:
-
GCGR E63 Cell line
-
A2780cis Cell Line
-
HCT 116 BRCA2 -/- 42 Cell Line
-
HCT 116 p300 KO [D10] Cell Line
3. Preclinical evaluation and translational research
Understanding how experimental findings relate to human disease is an important part of translational cancer research.
Preclinical and advanced patient-derived cell line (PDC) and xenograft (PDX) models, mouse models and cell lines, and PlasmaxTM, a physiologically relevant cell culture medium, that can allow the generation of more predictive data, improving clinical translation and help you investigate tumour heterogeneity, biomarkers, treatment response, efficacy and resistance, providing you with complementary evidence alongside other experimental approaches.
Explore key models below for confident translational research
-
CRUK0606 T1-R1 TRACERx lung cancer PDX
-
Plasmax™ cell culture medium
-
CMT 167 Cell Line
-
CRUK0772 T1-R1 TRACERx lung cancer PDX
Choosing the right research tool for your research
Drug efficacy and resistance
Improve clinical translation with more predictive data
Move from preclinical to clinical testing with more confidence with advanced patient-derived cell line (PDC) and xenograft (PDX) models, syngeneic murine models and physiologically relevant cell culture medium.
Investigate:
- Efficacy
- Drug sensitivity and resistance
- Metastatic progression
Explore key models below for drug efficacy and resistance
-
PEO1 Cell Line
-
PEO23 Cell Line
-
CRUK0606 T1-R1 TRACERx lung cancer PDX
-
CRUK0606 T1-R5 TRACERx lung cancer PDX
Complex tumour biology
Generate robust biological evidence across diverse and clinically relevant tumour contexts
Access clinically relevant patient-derived and other models that help tackle the challenges of tumour heterogeneity and complex tumour microenvironments, supporting more robust target validation across biological contexts.
Investigate:
- Tumour heterogeneity
- Tumour micro-environment
- Tumour evolution and adaptation
Planning your next oncology programme?
Whether you’re validating a target, evaluating a lead candidate or designing a new study, our scientific team can help identify suitable models and reagents from across the CancerTools portfolio.
Our team can help you explore the CancerTools portfolio based on your research requirements.

















